On December 7, 2025 Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) reproted an oral presentation on the opening day of the conference featuring the Phase I/II clinical results of LBL-034, a GPRC5D/CD3 bispecific antibody with a unique 2:1 structure and conditional activation, independently developed using the proprietary LeadsBody platform, for the treatment of relapsed/refractory multiple myeloma (RRMM) at the 67th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) ("ASH") held in Orlando, Florida, USA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The study, led by Professor Jin Lu of Peking University People’s Hospital and conducted across 17 centers in China, demonstrated that LBL-034 achieved favorable safety and highly encouraging anti-tumor activity, including in high-risk refractory subgroups, highlighting its potential as a best-in-class therapeutic candidate.
The key clinical highlights of LBL-034
Safe escalation to 1200 μg/kg with no DLTs or MTD reached.
Adverse events impacting quality of life were predominantly Grade 1–2 and occurred mainly during Cycle 1, with markedly lower incidence thereafter. Taste, skin, and nail toxicities were infrequent and generally self-resolving.
Strong efficacy across dose levels 400–1200 μg/kg (n=40).
ORR reached 82.5%, with ≥CR at 52.5%, ≥VGPR at 72.5%, and MRD negativity at 80.0%.
At 800 μg/kg, ORR and ≥CR were 90.9% and 63.6%, respectively.
Robust activity in difficult-to-treat RRMM subgroups.
Extramedullary disease (EMD): ORR 75.0%, including two sCRs. At 1200 μg/kg, ORR in EMD patients reached 100%, with rapid EMD lesion regression observed.
Prior BCMA-treated patients: ORR 85.7%, with CR/sCR 57.1%.
Durable clinical benefit.
Across the 400–1200 μg/kg range, the 12-month PFS rate was 61.2% (median follow-up: 9.6 months). At 400 μg/kg (n=11), median follow-up reached 13.1 months, with a 12-month PFS rate of 56.8%.
Executive Commentary
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated:
"We are delighted that the strong efficacy and clinical potential of LBL-034 have been recognized by the international scientific community. A Phase II trial evaluating the safety and efficacy of LBL-034 with a RP2D at 1200 μg/kg in 4 populations, including 4L+RRMM, 2L+RRMM with EMD, 4L+RRMM with prior BCMA therapy, and R/R Plasma Cell Leukopenia (PCL) is currently ongoing. With our focused and efficient clinical development strategy, we aim to deliver new treatment options to patients with multiple myeloma, particularly those who are refractory or have extramedullary disease, as quickly as possible."
About LBL-034
LBL-034 is a bispecific T-cell engager (TCE) that targets both GPRC5D and CD3, developed using the Company’s proprietary LeadsBody platform. Designed with a 2:1 binding format—two sites for GPRC5D and one for CD3—LBL-034 can selectively target GPRC5D+ cancer cells, conditionally activate T cells, reduce the risk of cytokine release, minimize the risk of systemic toxicity, and lower the risk of T cell exhaustion, thereby exerting anti-tumor effects in an efficient, low-toxic, and long-term stable manner.
In preclinical studies, LBL-034 has demonstrated strong efficacy signals, comparable to or exceeding those of leading competitors. The molecule is currently being evaluated in a Phase I/II clinical trial for relapsed or refractory multiple myeloma (RRMM) in China. According to Frost & Sullivan, as of November 2024, LBL-034 is the second most clinically advanced GPRC5D-targeted CD3 T-cell engager globally. In October 2024, LBL-034 received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of multiple myeloma.
(Press release, Nanjing Leads Biolabs, DEC 7, 2025, View Source [SID1234661218])